Sabra Health Care REIT (SBRA) Q2 2026 Earnings Call Transcript

Sabra Health Care REIT reported Q2 2026 normalized FFO per share of $0.38 and normalized AFFO per share of $0.40, with cash NOI rising $5.6M sequentially to $144.3M, supported by 88.2% same-store occupancy (+170 bps YoY) and 13.7% same-store managed senior housing Cash NOI growth. The company reaffirmed 2026 guidance for 7%–8% normalized FFO/AFFO growth (midpoint ~7% FFO and ~8% AFFO), declared a $0.30 quarterly dividend (75% payout of Q2 normalized AFFO), and reduced leverage to 4.61x from 5.04x. Investment activity stayed strong with ~$274.1M invested in Q2 and ~$223.0M after quarter-end (YTD ~$599.0M) while maintaining $1.3B liquidity via cash, credit capacity, and forward ATM availability.

Analysis

SBRA is transitioning from a balance-sheet repair story to a cash-flow compounding story. The key mechanism is mix shift: more SHOP exposure turns modest occupancy/rate gains into disproportionately faster NOI growth than the legacy fixed-rent book, so the next 1-3 quarters are likely to be driven by operating leverage rather than pure acquisition math. The leverage step-down also matters because it removes the near-term need to force equity issuance, which should support multiple stability into year-end.

Second-order, SBRA's stronger capital position should let it keep buying from smaller operators that need liquidity or succession solutions, which is exactly where the best spreads are likely to be. That favors larger REITs with execution capability and hurts slower-growth peers whose portfolios are still dominated by contractual rent and/or weaker SNF exposure. In the near term, the stock can work on the combination of dividend coverage, visible pipeline closes, and the Avamere reset; over 6-18 months, the market should start capitalizing 2027/2028 earnings power rather than just 2026 guidance.

The contrarian risk is that consensus may be underestimating dilution and overestimating persistence of the current operating tailwind. Forward equity is latent supply, and SHOP margins remain exposed to wage inflation and occupancy normalization; if RevPOR slows to low-single digits or same-store occupancy stalls below the high-80s, the rerating should pause. Falsifiers to watch: leverage moving back above 5x, delayed closings, or any evidence that the mid-teens IRR pipeline is compressing toward high single digits.

Key Decisions for Investors

• Buy SBRA common on post-earnings weakness, 1-3 month horizon, targeting a rerate into year-end pipeline closes and the Avamere step-up; cut if same-store occupancy stalls or RevPOR decelerates sharply.
• Pair trade: long SBRA / short OHI, 3-6 months, to express better growth, better balance-sheet flexibility, and lower operator-credit drag versus the more SNF-heavy peer; thesis breaks if OHI stabilizes credits while SBRA SHOP margins soften.
• If you want defined risk, use a bullish SBRA call spread expiring after the Q4 catalyst window rather than chasing common after the move; the trade is about multiple expansion on 2027 visibility, not just 2026 EPS.
• Set an alert to reduce exposure if SBRA leverage re-approaches 5x or if forward equity issuance accelerates faster than acquisition funding needs; that would signal dilution is again becoming the marginal funding source.
• Watch the healthcare REIT basket for relative outperformance versus slower-growth names (e.g., OHI, NHI) as a confirmation trade; if SBRA fails to outperform after the call, the market is likely questioning the durability of SHOP margin expansion.